News/ News/ Oncology

Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal

, , , , 0 Comment

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics